NPPA fixed retail price of 19 formulations: January 2024

Last Updated on January 16, 2024 by The Health Master

NPPA

Download NPPA notification No. S.O. 15 (E) dt 01-01-2024, the link is given below: The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 19 formulations under the Drugs (Prices Control) Order, 2013, vide S.O. 15(E) dt 01-01-2024 based on the decision of 119th Authority meeting dated 15.12.2023.

The notification states as follows:

In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

A table is given below the article

Note:

(a) The manufacturer of the above-mentioned formulations, i.e., the “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add Goods and Services Tax only if they have actually paid it or it is payable to the Government on the retail price mentioned in column (6) of the above-mentioned table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013.

The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above, i.e., those who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to the fulfillment of all the applicable statutory requirements as laid down by the government under relevant statutes or rules,
including manufacturing license permission from the competent authority, i.e., the central or state licensing authority, as may be applicable, by the concerned manufacturer/marketing company.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per the instant price notification and notes specified hereinabove, then the concerned manufacturer / marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of the manufacturer and marketing company specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer and marketing company
Companies as specified in corresponding entries in Columns (2), (3), and (5) thereof, if any, issued prior to this notification, stand superseded.

Table

Sl. No .	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1	Bisoprolol Fumarate & Amlodipine tablet	Each film coated tablet contains: Bisoprolol Fumarate IP 2.5mg Amlodipine Besylate IP Eq. to Amlodipine 5mg	1 Tablet	M/s Swiss Garnier Biotech Private Limited / M/s Zydus Healthcare Limited	6.74
2	Aceclofenac + Paracetamol + Serratiopeptid ase Tablet	Each film coated tablet contains: Aceclofenac IP 100mg, Paracetamol IP 325mg Serratiopeptidase IP 15mg (As enteric coated granules eq. to 30000 enzyme activity unity of serratiopeptidase)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. /M/s Apex Laboratories Private Limited	8.00
3	Povidone Iodine Gargle	Povidone Iodine Gargle Composition: Povidone-Iodine IP 2% w/v (Available Iodine 0.2w/v)	1 ml	M/s Stedman Pharmaceuticals Pvt. Ltd.	1.93
4	Amoxycillin + Potassium Clavulanate Tablets IP	Each film coated tablet contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 875mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125mg	1 Tablet	M/s Theon Pharmaceuticals Ltd. / M/s J.B. Chemicals & Pharmaceuticals Ltd.	40.03
5	Bilastine and Montelukast Tablets	Each film coated tablet contains: Montelukast Sodium IP Eq. to Montelukast 10mg Bilastine 20mg	1 Tablet	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Cadila Pharmaceuticals Ltd.	13.02
6	Telmisartan and Metoprolol Succinate (ER) Tablet	Each film coated bilayered tablet contains: Telmisartan IP 40mg Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate 50mg (as extended release form)	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd. / M/s La Renon Healthcare Pvt. Ltd.	13.39
7	Metoprolol Succinate Extended Release & Cilnidipine Tablet	Each film coated bilayered tablet contains:Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate IP 25mg (As Extended release form) Cilnidipine IP 10mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Cipla Limited	9.12
8	Metoprolol Succinate Extended Release & Cilnidipine Tablet	Each film coated bilayered tablet contains: Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate 50mg (As Extended release form) Cilnidipine IP 10mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Cipla Limited	10.21
9	Trastuzumab 150mg	Combipack of Each pack contains: Vial-1 Lyophilized Powder for concentrate for solution for Intravenous Infusion, Multi use vial Composition: Trastuzumab (r-DNA Origin) IH (Active ingredient) 150mg, α,α-Trehalose Dihydrate USP (as Lyoprotectant) 136.2mg L-Histidine Hydrochloride Monohydrate EP (as buffering agent) 3.36mg L-Histidine USP (as buffering agent) 2.16mg Polysorbate 20 IP (as surfactant) 0.6mg Vial -2 Bacteriostatic Water for Injection 10 ml Single use vial Composition: Benzyl Alcohol IP 1.1% V/V Water for Injection	1 Vial	M/s Hetero Biopharma Limited / M/s Mankind Pharma Limited	15817 .49
10	Sucralfate, Metronidazole and Lignocaine Hydrochloride Cream	Composition:Sucralfate IP 7.0% w/wMetronidazole IP 1.0% w/w Lignocaine Hydrochloride IP 4.0% w/wCream base q.s.	Per Gram	M/s Stedman Pharmaceuticals Pvt. Ltd.	4.45

11	Bisoprolol Fumarate and Telmisartan Tablets	Each film coated tablet contains: Bisoprolol Fumarate IP 2.5 mg Telmisartan IP 40 mg	1 Tablet	M/s Ravenbhel Healthcare Pvt Ltd / M/s La Renon Healthcare Pvt Ltd	9.73
12	Bisoprolol Fumarate and Telmisartan Tablets	Each film coated tablet contains: Bisoprolol Fumarate IP 5 mg Telmisartan IP 40 mg	1 Tablet	M/s Ravenbhel Healthcare Pvt Ltd / M/s La Renon Healthcare Pvt Ltd	11.22
13	Bisoprolol Fumarate and Telmisartan Tablets	Each film coated bilayered tablet contains: Bisoprolol Fumarate IP 2.5 mg Telmisartan IP 40 mg	1 Tablet	M/s Mascot Health Series Pvt. Ltd. / M/s Zydus Healthcare Ltd.	9.73
14	Bisoprolol Fumarate and Telmisartan Tablets	Each film coated bilayered tablet contains: Bisoprolol Fumarate IP 5 mg Telmisartan IP 40 mg	1 Tablet	M/s Mascot Health Series Pvt. Ltd. / M/s Zydus Healthcare Ltd.	11.22
15	Norethisterone Acetate Controlled Release Tablet	Each Film Coated Controlled Release tablet contains: Norethisterone Acetate BP 10mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Group Pharmaceuticals Ltd.	15.80
16	Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate Oral Suspension	Each 5 ml contains: Sodium Alginate IP 250mg Sodium Bicarbonate IP 133.5mg Calcium Carbonate IP 80mg	1 ml	M/s Skymap Pharmaceuticals Pvt. Ltd.	0.90
17	Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate Oral Suspension	Each 5 ml contains: Sodium Alginate IP 250mg Sodium Bicarbonate IP 133.5mg Calcium Carbonate IP 80mg	1 ml	M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd.	0.90
18	Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate Oral Suspension	Each 5 ml contains: Sodium Alginate IP 250mg Sodium Bicarbonate IP 133.5mg Calcium Carbonate IP 80mg	1 ml	M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Jagsonpal Pharmaceuticals Ltd.	0.90
19	Albendazole & Ivermectin Tablets	Each uncoated chewable tablet contains: Albendazole IP 400mg Ivermectin IP 6mg	1 Tablet	M/s IBN Herbals (A unit of Curetech Formulation (P) Ltd.) / M/s Indoco Remedies Limited	24.63

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

For informative videos by The Health Master, click on the below YouTube icon:

• Key Notes on Revised Schedule M: Point No. 14 – Materials
  December 25, 2024
• USFDA issues VAI status to Biocon for Bengaluru API facility
  December 25, 2024
• Bulk drug import from China continues to rise in 5 years
  December 25, 2024
• High Court stays action against Pharma Units manufacturing Nutraceuticals
  December 25, 2024
• NPPA fixed retail price of 7 formulations: December 2024
  December 24, 2024
• Revised Schedule M: Industry seeks balance between Quality and Viability
  December 24, 2024

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

For informative videos on consumer awareness, click on the below YouTube icon: